Výsledky vyhledávání - "Nader E. Abo-Dya"

Akademický článek

Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist: simulation-guided analogue design and pharmacological screening

Autor: Khalid A. Agha, Nader E. Abo-Dya, Abdul Rashid Issahaku, Clement Agoni, Mahmoud E. S. Soliman, Eatedal H. Abdel-Aal, Zakaria K. Abdel-Samii, Tarek S. Ibrahim

Publikováno v: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 1241-1256 (2022)

An efficient method for synthesising NMDAR co-agonist Sunifiram (DM235), in addition to Sunifram-carbamate and anthranilamide hybrids, has been developed in high yields via protecting group-free stepwise unsymmetric diacylation of piperazine using N-

Externí odkaz: https://doaj.org/article/4e635989cfea448eab1877e1019864be

Zobrazit plný text záznamu

Akademický článek

The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)’s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19

Autor: Kamel Metwally, Nader E. Abo-Dya, Mohammed Issa Alahmdi, Maha Z. Albalawi, Galal Yahya, Aimen Aljoundi, Elliasu Y. Salifu, Ghazi Elamin, Mahmoud A. A. Ibrahim, Yasien Sayed, Sylvia Fanucchi, Mahmoud E. S. Soliman

Publikováno v: Molecules, Vol 28, Iss 6, p 2806 (2023)

The unusual and interesting architecture of the catalytic chamber of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was recently explored using Cryogenic Electron Microscopy (Cryo-EM), which revealed the presence of two distinctive binding caviti

Externí odkaz: https://doaj.org/article/a3686c20460b45f7b706fbd4b5d44f8d

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Bridging the Gap in Malaria Parasite Resistance, Current Interventions, and the Way Forward from in Silico Perspective: A Review

Autor: Ransford Oduro Kumi, Belinda Oti, Nader E. Abo-Dya, Mohamed Issa Alahmdi, Mahmoud E. S. Soliman

Publikováno v: Molecules, Vol 27, Iss 22, p 7915 (2022)

The past decade has seen most antimalarial drugs lose their clinical potency stemming from parasite resistance. Despite immense efforts by researchers to mitigate this global scourge, a breakthrough is yet to be achieved, as most current malaria chem

Externí odkaz: https://doaj.org/article/bdcbadc3cb8642e6b14b16846aac599a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design

Autor: Mahmoud E.S. Soliman, Preantha Poonan, Xylia Q. Peters, Mohamed I. Alahmdi, Nader E. Abo-Dya

Publikováno v: Anti-Cancer Agents in Medicinal Chemistry. 23:953-966

Background: Heterozygous mutations in the cytoplasmic and mitochondrial isoforms of isocitrate dehydrogenase enzymes 1 and 2 subtypes have been extensively exploited as viable druggable targets, as they decrease the affinity of isocitrate and higher

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d18778ba2bf1231b5c9b59d5060970
https://doi.org/10.2174/1871520623666221129163001

Zobrazit plný text záznamu

Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl) phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights

Autor: Mahmoud Soliman, Xylia Quintina Peters, Preantha Poonan, Elliasu Salifu Yakubu, Mohamed Issa Alahmdi, Nader E. Abo-Dya

Publikováno v: Current Pharmaceutical Biotechnology. 24

Background:: Tankyrases (TNKS) are homomultimers existing in two forms, viz. TNKS1 and TNKS2. TNKS2 plays a pivotal role in carcinogenesis by activating the Wnt//β-catenin pathway. TNKS2 has been identified as a suitable target in oncology due to it

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd71f0ae415cb5500aae151b45a26051
https://doi.org/10.2174/1389201024666230330084017

Zobrazit plný text záznamu

Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective inhibition to the BTK/HCK Dual inhibition- Delving into the Inhibitory Activity of KIN-8194 Against BTK, and HCK in the Treatment of Mutated 〖BTK〗^Cys481 Waldenström Macroglobulinemia: A computational Approach

Autor: Mahmoud Soliman, Ghazi Elamin, Aimen Aljoundi, Mohamed Alahmdi, Nader E. Abo-Dya

Publikováno v: Anti-Cancer Agents in Medicinal Chemistry. 23

Background: Despite the early success of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of Waldenström macroglobulinemia (WM), these single-target drug therapies have limitations in their clinical applications, such as drug resistance. S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e51ecdd73d7ac63bc4e8e2ae17e3f1dd
https://doi.org/10.2174/1871520623666230208102609

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání